Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study

Show other versions (1)

CorrigendumHuang L, Li GM, Zhu JY, Li Z, Li T, Leng XS. OncoTargets and Therapy 2012, 5:457–462.Paper listed as a "Review" in error, should have been listed as "Original Research".Read the original article

Bibliographic Details
Main Authors:	Huang L, Li GM, Zhu JY, Li Z, Li T, Leng XS
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-04-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/ott-31387-efficacy-of-ssorafenib-after-liver-transplancorrigendum-a12747

Similar Items

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study
by: Huang L, et al.
Published: (2012-12-01)

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern]
by: Huang L, et al.
Published: (2020-04-01)

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum]
by: Huang L, et al.
Published: (2020-05-01)

Clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinoma exceeding Milan criteria: a comparative study
by: LIU Jianyong
Published: (2014-09-01)

Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study
by: Teng Chieh-Lin, et al.
Published: (2012-02-01)

Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States
by: Supriya S. Patel, et al.
Published: (2012-01-01)

Stick to Milan: Infeasibility of the Brazil-Milan Criteria in recommending patients with hepatocellular carcinoma for liver transplantation
by: Alexander Clevewood Ng
Published: (2021-11-01)

Short- and Long-term Outcomes between Young and Older HCC Patients Exceeding The Milan Criteria after Hepatectomy
by: Junyi Shen, et al.
Published: (2018-01-01)

Liver transplantation and expanded Milan criteria: does it really work?
by: Marina Vilela Chagas Ferreira, et al.
Published: (2012-09-01)

Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: retrospective study of the Milan and Hangzhou criteria.
by: Zhenhua Hu, et al.
Published: (2014-01-01)

Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review
by: Pierluigi Toniutto, et al.
Published: (2021-08-01)

Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?
by: Mehmet Haluk Morgul, et al.
Published: (2020-07-01)

International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria
by: Helena Degroote, et al.
Published: (2021-10-01)

Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model
by: Bleuenn Brusset, et al.
Published: (2021-05-01)

Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria
by: Altan Alim MD, et al.
Published: (2021-04-01)

THE EVOLUTION OF CRITERIA FOR LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA: FROM MILAN TO SAN FRANCISCO AND ALL AROUND THE WORLD!
by: Ioannis A. Ziogas, et al.
Published: (2017-09-01)

Retraction: Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria.
by: PLOS ONE Editors
Published: (2019-01-01)

Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria
by: Young Ri Kim, et al.
Published: (2018-05-01)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
by: Koen G. A. M. Hussaarts, et al.
Published: (2021-01-01)

Preoperative Alfa-Fetoprotein and Fibrinogen Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation Regardless of the Milan Criteria: Model Development with External Validation
by: Nan Jiang, et al.
Published: (2018-07-01)

Milan-out Criteria and Worse Intention-to-Treat Outcome Postliver Transplantation
by: Julia Herreras, MD, et al.
Published: (2019-10-01)

Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
by: Yoo EJ, et al.
Published: (2013-06-01)

Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma
by: Kirti Shetty, et al.
Published: (2014-01-01)

Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy
by: Ni JY, et al.
Published: (2019-11-01)

A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation
by: Malin Sternby Eilard, et al.
Published: (2019-06-01)

Pretransplantation α-fetoprotein level as a predictor of hepatocellular carcinoma recurrence after adult living donor liver transplantation within milan criteria in egyptian patients
by: Magdy Galal, et al.
Published: (2019-01-01)

Effectiveness of Sorafenib in Hepatic Hemangioma
by: Prateek Tiwari, et al.
Published: (2017-05-01)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
by: Khaldoun Almhanna, et al.
Published: (2009-11-01)

An Exceedingly Rare Case of Liraglutide-Induced Liver Injury
by: Swetha Parvataneni, et al.
Published: (2021-01-01)

Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.
by: Sangheun Lee, et al.
Published: (2013-01-01)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
by: Yang Zhao, et al.
Published: (2019-05-01)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
by: Fei-Xiang Wu, et al.
Published: (2017-09-01)

Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial
by: Kwang-Woong Lee, et al.
Published: (2020-10-01)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
by: L. Barbier, et al.
Published: (2011-01-01)

Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria.
by: Guanghua Rong, et al.
Published: (2015-01-01)

Microwave ablation resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis
by: Wenwu Liu, et al.
Published: (2019-09-01)

Research advances in sorafenib combined with orthotopic liver transplantation, radiofrequency ablation, and transarterial chemoembolization in treatment of hepatocellular carcinoma
by: ZHANG Mingjuan
Published: (2014-08-01)

Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression
by: Shouhua Zhang, et al.
Published: (2021-03-01)

Clinical effect of surgical resection versus radiofrequency ablation in treatment of multiple liver cancer in different liver segments meeting the Milan criteria
by: WANG Ning
Published: (2020-04-01)

Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment
by: Bo Chen, et al.
Published: (2020-08-01)